Developer docs
API playgroundTry for free, no card

Search company profiles

Biofidus

Full company profile

uuid000neb6

Namestring
Biofidus
Legal namestring
Biofidus AG
Websiteurl
biofidus.de
Company typeenum
Private
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBielefeld, Germany
HQ citystring
Bielefeld
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioanalytical services, biologics characterization, biosimilar studies, contract research, antibody characterization
Industry2 codes
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Contract Research / Bioanalytical Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1CRO Analytical Services
TypeProfessional Services
Description

Contract research organization providing fee-for-service analytical testing and characterization studies for biopharmaceutical clients. Revenue generated through project-based engagements for structural and functional analysis of biologics, biosimilars, and cell/gene therapies.

biofidus.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Biofidus is a contract research organization (CRO) providing fee-for-service bioanalytical testing and characterization studies for biopharmaceutical clients. The company delivers a holistic analytical platform covering 150+ services across four pillars — Studies (biosimilar, developability, stability, lead/clone selection), Biologics (antibody, multispecific, ADC, nanobody, fusion protein, peptide/hormone, AAV/CGT characterization), Popular Analytical Services (protein sequencing, SPR, cell-based assays, glycosylation, CE, aggregation, higher order structure, impurity analysis), and Small Molecules (spent media, neurotransmitter, metabolite, vitamin analysis). Services target pharmaceutical and biotechnology companies developing New Biological Entities, biosimilars, and cell and gene therapies from early-stage R&D through regulatory submission.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 1000+ projects completed
+3 more records
Product overview1 text field

Biofidus is a Contract Research Organization (CRO) offering a holistic analytical service platform spanning from discovery to commercialization. The company provides integrated service modules organized into four main categories: Studies (Biosimilar Studies, Developability Studies, Stability Studies, Lead and Clone Selection), Biologics (Antibody Characterization, Multispecific Antibodies, Nanobodies, ADC Analysis, Fusion Proteins, Enzymes, Peptides and Hormones, AAV and CGT Services), Popular Analytical Services (including Protein Sequencing, SPR Analysis, Cell-Based Assays, Bioactivity Studies, Glycosylation Analysis, and more), and Small Molecules (Spent Media, Neurotransmitter, Metabolites, Vitamins). The platform is designed to support New Biological Entities (NBEs) and biosimilars development, providing comprehensive structural and functional characterization from early analytics through robust data packages for regulatory submission.

Product and service4 records
1Studies Service Line
CategoryContract Research / Bioanalytical Services
Description

Project-based analytical study packages for biologics and biosimilar development, including biosimilar comparability studies, developability assessment, forced degradation and stability studies, and lead candidate and cell clone selection. Targeted at pharmaceutical and biotech sponsors progressing NBEs and biosimilars through early and late development.

2Biologics Characterization Service Line
CategoryContract Research / Bioanalytical Services
Description

Analytical characterization services organized by therapeutic modality, including IgG and multispecific antibody characterization, antibody-drug conjugate (ADC) analysis, nanobody characterization, enzyme characterization, fusion protein analysis, peptide and hormone analysis, and AAV and cell and gene therapy (CGT) vector analysis. Aimed at sponsors developing complex biologics across multiple modalities.

3Popular Analytical Services
CategoryContract Research / Bioanalytical Services
Description

Individual analytical assays available as standalone service modules: protein sequencing (N-terminal and full-length), SPR analysis for binding kinetics, cell-based assays, bioactivity studies, amino acid modifications and PTM analysis, glycosylation analysis, capillary electrophoresis (CE) analysis, aggregation analysis, charge heterogeneity analysis, DNA/RNA sequencing, higher order structure characterization, impurity analysis, and serum and plasma assays for PK/PD studies. Individual assays can be contracted per project for biologics characterization and regulatory data packages.

4Small Molecules Analytical Services
CategoryContract Research / Bioanalytical Services
Description

Small-molecule analytical services including spent media analysis (cell culture media components and metabolites for bioprocess optimization), neurotransmitter quantification, metabolite identification and quantification in biological systems, and vitamin analysis for quantification and characterization across matrices. Targeted at sponsors requiring complementary small-molecule analytics alongside biologics work.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic merger combining Biofidus' deep analytical expertise with Midas Pharma's broad regulatory and commercialization capabilities. Together they provide seamless support across the full product lifecycle from early development through commercialization. This partnership enhances the holistic analytical platform with regulatory guidance and commercialization support.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint scientific collaboration resulting in published workflow for ADCC-enhanced antibody development. The publication 'Screen, Select, Enhance: A joint evitria AG – Biofidus workflow for ADCC‑enhanced antibody development' demonstrates co-development of analytical methods for antibody-dependent cellular cytotoxicity enhancement.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global testing and quality assurance provider with bioanalytical and biologics characterization services supporting pharma development and release. Competes for outsourced analytical and stability work.

TypeEmerging player
Description

Reagents, assays, and analytical tools provider for protein and cell-based research. Overlaps with Biofidus in protein characterization workflows and competes in the same research customer base.

TypeBroad incumbent
Description

Global testing, inspection, and certification company with a health sciences division providing bioanalytical, biopharma, and clinical trial services. Competes for biologics characterization and biosimilar analytical work.

TypeBroad incumbent
Description

Global biologics CDMO/CRO offering bioanalytical, characterization, and biosimilar development services at very large scale. Competes on capacity and integrated end-to-end biologics offerings.

5Protagen Protein Services
TypeDirect peer
Description

Specialist bioanalytical CRO focused on protein characterization, biosimilar comparability, and biologics analytics. Direct competitor to Biofidus in the same German/European specialty bioanalytical niche.

TypeBroad incumbent
Description

Major CRO with broad biopharma services including bioanalytical, biologics characterization, and biosafety testing. Competes with Biofidus for outsourced analytical work from large pharma and biotech clients.

TypeDirect peer
Description

European bioanalytical CRO providing PK/PD, immunogenicity, and biologics characterization services. Direct peer in the regional specialty bioanalytical CRO market served by Biofidus.

TypeBroad incumbent
Description

Bioprocessing and analytics provider offering chromatography-based analytical solutions for biologics and gene therapies. Adjacent competitor in analytics and purification characterization for complex biologics.

TypeBroad incumbent
Description

Global laboratory services group with a large bioanalytical and biopharma product testing business serving pharma and biotech across drug development. Competes on scale, geographic reach, and integrated service breadth.

TypeRegional player
Description

Central European CRO with bioanalytical and drug discovery services. Comparable in size and positioning as a regionally focused, science-led CRO serving pharma and biotech clients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biofidus

Contract Research / Bioanalytical Servicesbiofidus.de

Biofidus firmographics

Firmographics
Name
Biofidus
Legal name
Biofidus AG
Website
https://biofidus.de
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Biofidus industry classification

Industry
Product category
Contract Research / Bioanalytical Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing

Keywords

  • Bioanalytical services
  • Biologics characterization
  • Biosimilar studies
  • Contract research
  • Antibody characterization

Where Biofidus is headquartered

Location

Headquarters

HQ city
Bielefeld
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Biofidus business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. CRO Analytical Services: Contract research organization providing fee-for-service analytical testing and characterization studies for biopharmaceutical clients. Revenue generated through project-based engagements for structural and functional analysis of biologics, biosimilars, and cell/gene therapies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Biofidus product offering

Product offering

Core offering

Biofidus is a contract research organization (CRO) providing fee-for-service bioanalytical testing and characterization studies for biopharmaceutical clients. The company delivers a holistic analytical platform covering 150+ services across four pillars — Studies (biosimilar, developability, stability, lead/clone selection), Biologics (antibody, multispecific, ADC, nanobody, fusion protein, peptide/hormone, AAV/CGT characterization), Popular Analytical Services (protein sequencing, SPR, cell-based assays, glycosylation, CE, aggregation, higher order structure, impurity analysis), and Small Molecules (spent media, neurotransmitter, metabolite, vitamin analysis). Services target pharmaceutical and biotechnology companies developing New Biological Entities, biosimilars, and cell and gene therapies from early-stage R&D through regulatory submission.

Product overview

Biofidus is a Contract Research Organization (CRO) offering a holistic analytical service platform spanning from discovery to commercialization. The company provides integrated service modules organized into four main categories: Studies (Biosimilar Studies, Developability Studies, Stability Studies, Lead and Clone Selection), Biologics (Antibody Characterization, Multispecific Antibodies, Nanobodies, ADC Analysis, Fusion Proteins, Enzymes, Peptides and Hormones, AAV and CGT Services), Popular Analytical Services (including Protein Sequencing, SPR Analysis, Cell-Based Assays, Bioactivity Studies, Glycosylation Analysis, and more), and Small Molecules (Spent Media, Neurotransmitter, Metabolites, Vitamins). The platform is designed to support New Biological Entities (NBEs) and biosimilars development, providing comprehensive structural and functional characterization from early analytics through robust data packages for regulatory submission.

Differentiator

Problem solved

Functional benefit

Products and services

  • Studies Service Line Project-based analytical study packages for biologics and biosimilar development, including biosimilar comparability studies, developability assessment, forced degradation and stability studies, and lead candidate and cell clone selection. Targeted at pharmaceutical and biotech sponsors progressing NBEs and biosimilars through early and late development.
  • Biologics Characterization Service Line Analytical characterization services organized by therapeutic modality, including IgG and multispecific antibody characterization, antibody-drug conjugate (ADC) analysis, nanobody characterization, enzyme characterization, fusion protein analysis, peptide and hormone analysis, and AAV and cell and gene therapy (CGT) vector analysis. Aimed at sponsors developing complex biologics across multiple modalities.
  • Popular Analytical Services Individual analytical assays available as standalone service modules: protein sequencing (N-terminal and full-length), SPR analysis for binding kinetics, cell-based assays, bioactivity studies, amino acid modifications and PTM analysis, glycosylation analysis, capillary electrophoresis (CE) analysis, aggregation analysis, charge heterogeneity analysis, DNA/RNA sequencing, higher order structure characterization, impurity analysis, and serum and plasma assays for PK/PD studies. Individual assays can be contracted per project for biologics characterization and regulatory data packages.
  • Small Molecules Analytical Services Small-molecule analytical services including spent media analysis (cell culture media components and metabolites for bioprocess optimization), neurotransmitter quantification, metabolite identification and quantification in biological systems, and vitamin analysis for quantification and characterization across matrices. Targeted at sponsors requiring complementary small-molecule analytics alongside biologics work.

Quantifiable outcome

  • 1000+ projects completed
  • +3 more outcomes

Companies that use Biofidus

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Biofidus technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Biofidus partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Midas PharmacoreStrategic or Co-development PartnerStrategic merger combining Biofidus' deep analytical expertise with Midas Pharma's broad regulatory and commercialization capabilities. Together they provide seamless support across the full product lifecycle from early development through commercialization. This partnership enhances the holistic analytical platform with regulatory guidance and commercialization support.
  • Evitria AGminorStrategic or Co-development PartnerJoint scientific collaboration resulting in published workflow for ADCC-enhanced antibody development. The publication 'Screen, Select, Enhance: A joint evitria AG – Biofidus workflow for ADCC‑enhanced antibody development' demonstrates co-development of analytical methods for antibody-dependent cellular cytotoxicity enhancement.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Biofidus competitors and assessment

Company assessment

Broad incumbents

  • Intertek Pharmaceutical Services: Global testing and quality assurance provider with bioanalytical and biologics characterization services supporting pharma development and release. Competes for outsourced analytical and stability work.
  • SGS Health Sciences: Global testing, inspection, and certification company with a health sciences division providing bioanalytical, biopharma, and clinical trial services. Competes for biologics characterization and biosimilar analytical work.
  • WuXi Biologics: Global biologics CDMO/CRO offering bioanalytical, characterization, and biosimilar development services at very large scale. Competes on capacity and integrated end-to-end biologics offerings.
  • Charles River Laboratories: Major CRO with broad biopharma services including bioanalytical, biologics characterization, and biosafety testing. Competes with Biofidus for outsourced analytical work from large pharma and biotech clients.
  • Sartorius (BIA Separations): Bioprocessing and analytics provider offering chromatography-based analytical solutions for biologics and gene therapies. Adjacent competitor in analytics and purification characterization for complex biologics.
  • Eurofins Bioanalytical Services: Global laboratory services group with a large bioanalytical and biopharma product testing business serving pharma and biotech across drug development. Competes on scale, geographic reach, and integrated service breadth.

Emerging players

  • Bio-Techne: Reagents, assays, and analytical tools provider for protein and cell-based research. Overlaps with Biofidus in protein characterization workflows and competes in the same research customer base.

Direct peers

  • Protagen Protein Services: Specialist bioanalytical CRO focused on protein characterization, biosimilar comparability, and biologics analytics. Direct competitor to Biofidus in the same German/European specialty bioanalytical niche.
  • Interpharma Praha (Bioanalytical): European bioanalytical CRO providing PK/PD, immunogenicity, and biologics characterization services. Direct peer in the regional specialty bioanalytical CRO market served by Biofidus.

Regional players

  • Selvita: Central European CRO with bioanalytical and drug discovery services. Comparable in size and positioning as a regionally focused, science-led CRO serving pharma and biotech clients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Biofidus social profiles

Digital presence

Biofidus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biofidus leadership team

Management profile

Number of profiles

Profiles8 records

Biofidus funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biofidus M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biofidus

What does Biofidus do?

Biofidus is a contract research organization (CRO) providing fee-for-service bioanalytical testing and characterization studies for biopharmaceutical clients. The company delivers a holistic analytical platform covering 150+ services across four pillars — Studies (biosimilar, developability, stability, lead/clone selection), Biologics (antibody, multispecific, ADC, nanobody, fusion protein, peptide/hormone, AAV/CGT characterization), Popular Analytical Services (protein sequencing, SPR, cell-based assays, glycosylation, CE, aggregation, higher order structure, impurity analysis), and Small Molecules (spent media, neurotransmitter, metabolite, vitamin analysis). Services target pharmaceutical and biotechnology companies developing New Biological Entities, biosimilars, and cell and gene therapies from early-stage R&D through regulatory submission.

Is Biofidus a public or private company?

Biofidus is a private company. It is classified as family owned and is currently operating.

When was Biofidus founded?

Biofidus was founded in 2015. It employs 11 to 50 people.

Where is Biofidus based?

Biofidus is headquartered in Bielefeld, Germany, in the Europe region.

How does Biofidus make money?

One revenue line is on record: CRO Analytical Services.

Who are Biofidus's main competitors?

Broad incumbents on record are Intertek Pharmaceutical Services, SGS Health Sciences, WuXi Biologics, Charles River Laboratories, Sartorius (BIA Separations) and Eurofins Bioanalytical Services. Bio-Techne is listed as an emerging player. Direct peers are Protagen Protein Services and Interpharma Praha (Bioanalytical). Selvita is listed as a regional player.

Does Biofidus have an API?

No public API is recorded for Biofidus.

What industry is Biofidus in?

Biofidus's product category is Contract Research / Bioanalytical Services. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales